
    
      This Phase 2 multi-centre study will be performed by 6 Canadian sites. It is an open-label,
      single-arm study in patients with Idiopathic Pulmonary Fibrosis (IPF) aged 40 years and
      older.

      The duration of study participation is approximately 20 weeks for each patient and comprises
      6 study visits.
    
  